Paper Details

  1. Home
  2. Paper Details

Sonidegib phosphate: new approval for basal cell carcinoma.

Author: TibesR

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

Sonidegib is a promising treatment for locally advanced or metastatic basal cell carcinoma (BCC). It works by blocking the hedgehog signaling pathway, which is often activated in BCC due to mutations in the Ptch gene. Sonidegib has shown good response rates in patients with BCC, but resistance can develop over time. Further research is needed to develop new treatment strategies for BCC patients who develop resistance to Sonidegib.
Paper Details　
Original Abstract of the Article :
Basal cell carcinoma (BCC), although mostly locally confined, is the most common cancer. Most BCCs harbor inactivating mutations in the membrane receptor/gene Ptch, thereby activating the Hedgehog signaling pathway (Hh) via the essential signaling molecule Smoothened (SMO). Novel small-molecule inhi...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1358/dot.2016.52.5.2470697

データ提供：米国国立医学図書館（NLM）

A New Weapon in the Fight Against Basal Cell Carcinoma

Basal cell carcinoma (BCC), a common skin cancer, has long been a thorn in the side of dermatologists. This study focuses on a new drug called sonidegib, a SMO inhibitor, which has shown significant promise in treating advanced and metastatic BCC. The study explores the mechanism of action, efficacy, and potential side effects of this drug. The use of sonidegib is like building a sandcastle in a desert oasis. It's not a permanent fix, but it can provide a valuable line of defense against BCC. SMO inhibitors have shown impressive results, with response rates ranging from 35-60%. However, resistance can develop over time, highlighting the need for continued research and development of new treatment strategies.

Sonidegib: A New Hope for Advanced BCC

The study highlights the potential of sonidegib as a valuable treatment option for locally advanced, unresectable, and metastatic BCC. This drug offers a new way to combat BCC, providing a crucial tool in the fight against this prevalent skin cancer.

Fighting BCC: A Desert of Challenges

This study reminds us that the battle against BCC is ongoing, and new strategies are needed to overcome resistance. The development of novel combination therapies and salvage strategies are crucial to the fight against BCC.

Dr.Camel's Conclusion

Sonidegib represents a valuable addition to the arsenal against basal cell carcinoma, but the fight against this disease is ongoing. Continued research is needed to address the issue of resistance and to explore new strategies for managing this prevalent cancer.

Date :
  1. Date Completed 2016-09-06
  2. Date Revised 2019-12-10
Further Info :

Pubmed ID

27376162

DOI: Digital Object Identifier

10.1358/dot.2016.52.5.2470697

Related Literature

Article Analysis
・Side Effects of sonidegib
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.